Mostrar el registro sencillo del ítem

Artículo

dc.creatorTrujillo-Rodriguez, Mariaes
dc.creatorMuñoz Muela, Esperanzaes
dc.creatorSerna Gallego, Anaes
dc.creatorPraena Fernández, Juan Manueles
dc.creatorPérez Gómez, Albertoes
dc.creatorGasca-Capote, Carmenes
dc.creatorLópez Cortés, Luis Fernandoes
dc.date.accessioned2023-05-25T13:50:10Z
dc.date.available2023-05-25T13:50:10Z
dc.date.issued2022-07-14
dc.identifier.citationTrujillo-Rodriguez, M., Muñoz Muela, E., Serna Gallego, A., Praena Fernández, J.M., Pérez Gómez, A., Gasca-Capote, C. y López Cortés, L.F. (2022). Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients. PLoS ONE, 17 (7), e0269875. https://doi.org/10.1371/journal.pone.0269875.
dc.identifier.issn1932-6203es
dc.identifier.urihttps://hdl.handle.net/11441/146631
dc.description.abstractBackground The SARS-CoV-2 pandemic has overwhelmed hospital services due to the rapid transmission of the virus and its severity in a high percentage of cases. Having tools to predict which patients can be safely early discharged would help to improve this situation. Methods Patients confirmed as SARS-CoV-2 infection from four Spanish hospitals. Clinical, demographic, laboratory data and plasma samples were collected at admission. The patients were classified into mild and severe/critical groups according to 4-point ordinal categories based on oxygen therapy requirements. Logistic regression models were performed in mild patients with only clinical and routine laboratory parameters and adding plasma pro-inflammatory cytokine levels to predict both early discharge and worsening. Results 333 patients were included. At admission, 307 patients were classified as mild patients. Age, oxygen saturation, Lactate Dehydrogenase, D-dimers, neutrophil-lymphocyte ratio (NLR), and oral corticosteroids treatment were predictors of early discharge (area under curve (AUC), 0.786; sensitivity (SE) 68.5%; specificity (S), 74.5%; positive predictive value (PPV), 74.4%; and negative predictive value (NPV), 68.9%). When cytokines were included, lower interferon-γ-inducible protein 10 and higher Interleukin 1 beta levels were associated with early discharge (AUC, 0.819; SE, 91.7%; S, 56.6%; PPV, 69.3%; and NPV, 86.5%). The model to predict worsening included male sex, oxygen saturation, no corticosteroids treatment, C-reactive protein and Nod-like receptor as independent factors (AUC, 0.903; SE, 97.1%; S, 68.8%; PPV, 30.4%; and NPV, 99.4%). The model was slightly improved by including the determinations of interleukine-8, Macrophage inflammatory protein-1 beta and soluble IL-2Rα (CD25) (AUC, 0.952; SE, 97.1%; S, 98.1%; PPV, 82.7%; and NPV, 99.6%). Conclusions Clinical and routine laboratory data at admission strongly predict non-worsening during the first two weeks; therefore, these variables could help identify those patients who do not need a long hospitalization and improve hospital overcrowding. Determination of pro-inflammatory cytokines moderately improves these predictive capacities.es
dc.formatapplication/pdfes
dc.format.extent15 p.es
dc.language.isoenges
dc.publisherPublic Library of Sciencees
dc.relation.ispartofPLoS ONE, 17 (7), e0269875.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleClinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patientses
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.projectIDRH-0037-2020 a JVes
dc.relation.projectIDPY20/01276 a APGes
dc.relation.projectIDCP19/00159 a AGVes
dc.relation.projectIDCP19/00146 a ARes
dc.relation.projectIDFI19/00304 a EMMes
dc.relation.projectIDFI19/00083es
dc.relation.projectIDMCGC,RD16/0025/0020es
dc.relation.projectIDRD16/0025/0006es
dc.relation.projectIDRD16/0025/0026es
dc.relation.projectIDCB21/13/00020es
dc.relation.publisherversionhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0269875es
dc.identifier.doi10.1371/journal.pone.0269875es
dc.journaltitlePLoS ONEes
dc.publication.volumen17es
dc.publication.issue7es
dc.publication.initialPagee0269875es
dc.contributor.funderConsejería de Salud y Familiaes
dc.contributor.funderConsejería de Transformación Económica, Industria, Conocimiento y Universidadeses
dc.contributor.funderInstituto de Salud Carlos IIIes

FicherosTamañoFormatoVerDescripción
Clinical, laboratory data and ...1.433MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional